Newborn screening has been one of the great public health success stories of the 20th century. Since the introduction of phenylketonuria (PKU) screening in the 1960s, systematic screening programs have identified millions of affected infants before symptoms develop, enabling early treatment and preventing disability and death.
The Genomic Frontier
Now, whole-genome and whole-exome sequencing technologies are making it feasible to screen for hundreds — or even thousands — of conditions at once, rather than the 20–50 conditions covered by current biochemical screening panels.
Several large pilot programs are underway globally, including BabySeq in the US, the Generation Study in the UK, and various initiatives across Europe. These programs are generating crucial evidence on both the clinical utility and the ethical implications of genomic newborn screening.
Key Challenges
Variants of uncertain significance (VUS) remain a central challenge. Sequencing reveals many variants whose clinical significance is not yet established, creating difficult decisions for families and clinicians.
Health equity is another critical concern. Genomic reference databases are still heavily biased toward European ancestry populations, which may limit the accuracy of variant interpretation for diverse populations.
Psychological impact on families — particularly for conditions that manifest in adulthood or for which no treatment exists — requires careful ethical consideration and robust counselling infrastructure.
Looking Ahead
The question is no longer purely technological — the sequencing is feasible. The pressing questions are: Which conditions should we screen for? How do we handle incidental findings? How do we ensure equitable access?
These are the questions my research group is working on at the Institute of Human Genetics, University Hospital Heidelberg. I’ll be sharing more on our ongoing work in future posts.